View Post

Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

In Clinical Trials by Barbara Jacoby

From: apnews.com Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, will present updated interim results from a Phase II clinical trial of Puma’s drug neratinib at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting in Chicago. Neratinib was approved by the U.S. Food and Drug Administration (FDA) in July 2017 for the extended adjuvant treatment of adult patients …

View Post

Puma Biotechnology Announces Top Line Results of the Phase III NALA Trial of Neratinib in Patients with HER2-Positive Metastatic Breast Cancer

In Clinical Trials by Barbara Jacoby

SOURCE: Puma Biotechnology, Inc. From: apnews.com Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced top line results from the Phase III NALA trial of the Company’s lead drug candidate PB272 (neratinib) in patients with HER2-positive metastatic breast cancer who have failed two or more prior lines of HER2-directed treatments (third-line disease) in the setting of metastatic disease. The Phase …

View Post

Cancer Research Highlight: Puma Biotech’s Basket Pays Off

In Clinical Trials by Barbara Jacoby

By: Zach Hartman From: seekingalpha.com Summary Puma Biotechnology is known almost exclusively as a breast cancer company. New basket study results may portend a move outside of there, but you have to think outside the box. How relevant are HER2 mutations, though? Puma Biotechnology (PBYI) has made its entire game up on the back of one drug, a “pan-HER” inhibitor …

View Post

uBiome Announces First Stage of Companion Diagnostic Development in Collaboration with Puma Biotechnology, Inc.

In In The News by Barbara Jacoby

From: prweb.com uBiome, the leader in microbial genomics, today announced the first stage of companion diagnostic development with Puma Biotechnology, Inc. (NASDAQ: PBYI) to investigate the role of the microbiome in adverse events related to neratinib treatment of patients with HER2-positive breast cancer. “This companion diagnostic and clinical trial work is an important part of the future of uBiome,” said …

View Post

Puma Biotechnology Presents Results of Patient Reported Outcomes in Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

In Clinical Trials by Barbara Jacoby

From: businesswire.com Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, is presenting updated results from a Phase II clinical trial of Puma’s drug neratinib at the 2018 San Antonio Breast Cancer Symposium (SABCS) that is currently taking place in San Antonio, Texas. The presentation entitled, “The impact of neratinib with or without anti-diarrheal prophylaxis on health-related quality of life in …

View Post

Announcement: HER2+ Breast Cancer Program on Lifetime Channel Wednesday Oct 24th at 7:30 am ET/PT

In In The News by Barbara Jacoby

On behalf of Puma Biotechnology, I wanted to let you know of a program by Access Health on HER2+ Breast Cancer, airing on the Lifetime channel.  Puma was honored to sponsor this program which features Dr. Reshma Mahtani, Associate Professor, Silvestre Comprehensive Cancer Center, University of Miami.  In this program and during the interview, Dr. Mahtani will address the following …